Praxis Precision Medicines

Persistence Pays Off for Praxis as Essential Tremor Drug Succeeds in Two Pivotal Studies

Praxis Precision Medicines’ essential tremor drug ulixacaltamide met the goals of two Phase 3 clinical trials, paving the way for discussions with the FDA about a new drug application. The once-daily pill could become the first approved treatment for this movement disorder affecting an estimated 7 million Americans.

By Frank Vinluan

BioPharma

Praxis Presses Forward in Essential Tremor Despite Futility Finding From Trial Observers

A planned interim clinical trial analysis found Praxis Precision Medicines drug ulixacaltamide was unlikely to succeed as a treatment for essential tremor. But Praxis is continuing two late-stage tests of the drug; data are expected in the third quarter of 2025.

By Frank Vinluan